➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,685,980

Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,685,980
Title:Pyrrolopyrimidine compounds and their uses
Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. ##STR00001##
Inventor(s): Besong; Gilbert Ebai (Bad Duerkheim, DE), Brain; Christopher Thomas (North Reading, MA), Brooks; Clinton Alan (Smyrna, GA), Congreve; Miles Stuart (Royston, GB), Dagostin; Claudio (Cambridge, GB), He; Guo (Lexington, MA), Hou; Ying (Belmont, MA), Howard; Steven (Cambridge, GB), Li; Yue (Shanghai, CN), Lu; Yipin (Dublin, CA), Mortenson; Paul Neil (Cambridge, GB), Smith; Troy D. (Nashua, NH), Sung; Moo Je (Belmont, MA), Woodhead; Steven John (San Diego, CA), Wrona; Wojciech (Waltham, MA), Lagu; Bharat (Acton, MA)
Assignee: Novartis AG (Basel, CH) Astex Therapeutics, Ltd. (Cambridge, GB)
Application Number:13/060,154
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,685,980

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate TABLET, TABLET;ORAL 209935-001 May 4, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Novartis KISQALI ribociclib succinate TABLET;ORAL 209092-001 Mar 13, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,685,980

PCT Information
PCT FiledAugust 20, 2009PCT Application Number:PCT/EP2009/060793
PCT Publication Date:February 25, 2010PCT Publication Number: WO2010/020675

International Family Members for US Patent 8,685,980

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073116 ⤷  Free Forever Trial
Argentina 111763 ⤷  Free Forever Trial
Australia 2009284098 ⤷  Free Forever Trial
Brazil PI0917791 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.